Search
Cyclerion Therapeutics Inc
CYCNAdd to Watchlist
3.390USD
+0.035+1.04%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
14.68MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.04%
5 Days
+3.67%
1 Month
+7.62%
6 Months
+166.93%
Year to Date
+166.93%
1 Year
+16.49%
Key Figures
3.280Open
3.440High
15.63KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.41%Turnover Ratio
3.355Prev. Close
3.280Low
29.77KTurnover
LossP/E Static
1.43P/B
0.00%Div Yield TTM
-57.50%ROA
8.48052wk High
0.74Volume Ratio
-3.06MNet Profit
3.82MShares
-1.3055EPS TTM
1.80Beta
-67.77%ROE
1.02752wk Low
4.77%Amplitude
100.00%Gross Margin
14.68MMarket Cap
1.51Reward/Risk
5.90%Risk Rate
TradingKey Stock Score of Cyclerion Therapeutics Inc
Currency: USD Updated: 2026-06-30Key Insights
Cyclerion Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 214 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 8.00.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cyclerion Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cyclerion Therapeutics Inc Highlights
StrengthsRisks
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.07M.
Undervalued
The company’s latest PE is -2.60, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 318.08K shares, decreasing 67.72% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.98.
Analyst Rating
Based on
0
analysts
--
Current Rating
8.000
Target Price
+136.69%
Upside Space
Cyclerion Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cyclerion Therapeutics Inc Info
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Ticker SymbolCYCN
CompanyCyclerion Therapeutics Inc
CEOGraul (Regina M)
Websitehttps://www.cyclerion.com/
Related Instruments
-2.50%
-1.79%
-1.22%
-0.57%
-0.73%
-0.56%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
52161.500
-34.800 (-0.07%)
30096.400
-128.200 (-0.42%)
7469.200
-13.200 (-0.18%)
15295.000
-300.000 (-1.92%)
70621.000
-235.000 (-0.33%)
6319.000
-8.000 (-0.13%)
68.658
-1.263 (-1.81%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
3984.780
-22.500 (-0.56%)
FAQs
What is the current price of Cyclerion Therapeutics Inc (CYCN)?
The current price of Cyclerion Therapeutics Inc (CYCN) is 3.39.
What is the symbol of Cyclerion Therapeutics Inc?
The ticker symbol of Cyclerion Therapeutics Inc is CYCN.
What is the 52-week high of Cyclerion Therapeutics Inc?
The 52-week high of Cyclerion Therapeutics Inc is 8.48.
What is the 52-week low of Cyclerion Therapeutics Inc?
The 52-week low of Cyclerion Therapeutics Inc is 1.03.
What is the market capitalization of Cyclerion Therapeutics Inc?
The market capitalization of Cyclerion Therapeutics Inc is 12.95M.
What is the Earnings Per Share (EPS TTM) of Cyclerion Therapeutics Inc (CYCN)?
The Earnings Per Share (EPS TTM) of Cyclerion Therapeutics Inc (CYCN) is -1.11.